ApaTech, the rapidly growing orthobiologics company, was named Europe’s fastest growing Biotech/Pharmaceutical/Medical Technology/Equipment company
This annual ranking is based on a companies’ five-year revenue growth, for which ApaTech has achieved a rate of 8,318% over this period.
This achievement places ApaTech 9th overall in the ranking that includes the fastest growing public and private technology, media, telecommunications, life sciences and green technology companies from 26 countries in EMEA.
Simon Cartmell, ApaTech CEO commented: “This award demonstrates that a great product based on great technology, with a great team behind it can achieve incredible results. The determination to succeed is embedded in the fabric of our business and the people that work here; their passion and ambition are the reason for our success.”
“Because Deloitte Technology Fast 500 EMEA measures sustained revenue growth over five years, being one of the 500 fastest growing technology companies in EMEA is an impressive achievement,” said David Halstead, partner in charge of Deloitte’s Technology Fast 500 EMEA program.
“ApaTech deserves a lot of credit for its remarkable growth.”
The Deloitte Technology Fast 500 is the most objective industry-ranking standard to focus on the technology sector.
Entrants to the ranking must have been in business at least five years and have had base-year operating revenues of at least EUR50,000 and current year operating revenues of at least EUR800,000.
ApaTech is the developer and manufacturer of Actifuse(R), a unique fully synthetic silicate substituted calcium phosphate bone graft material for orthopaedic, spinal, dental and craniomaxillofacial applications.
The Actifuse scaffold mimics the body’s natural bony structure and accelerates the growth of high quality bone.
Actifuse is being used by surgeons in more than 30 countries around the world.
